IA
ADCT icon

IFP Advisors’s ADC Therapeutics ADCT Stock Holding History

IFP Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150 Buy
140
+110
+367% +$321 ﹤0.01% 4902
2026
Q1 		$112 Sell
30
-39
-57% -$154 ﹤0.01% 4720
2025
Q4 		$244 Buy
69
+39
+130% +$158 ﹤0.01% 4442
2025
Q3 		$120 Hold
30
– – ﹤0.01% 4513
2025
Q2 		$80 Buy
+30
New +$63 ﹤0.01% 4750

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IFP Advisors's ADCT Position: Q2 2026 in Review

IFP Advisors increased its ADC Therapeutics (ADCT) stake by 367% in Q2 2026, buying an estimated $321 and bringing the position to 140 shares worth $150. The position accounts for ﹤0.01% of the portfolio, ranked #4902.

IFP Advisors first reported a position in ADCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $244 in Q4 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • IFP Advisors held 140 shares of ADC Therapeutics worth $150 as of Q2 2026.
  • IFP Advisors bought 110 ADC Therapeutics shares in Q2 2026, an estimated $321.
  • ADC Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4902 holding.
  • IFP Advisors first reported a position in ADC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • IFP Advisors's ADC Therapeutics position peaked at $244 in Q4 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.